SQUAWK/NEWS
Account
Account
Menu
Live NewsCategoriesequity

Nektar Therapeutics (NKTR) News

Track canonical SquawkNews coverage tagged to NKTR, Nektar Therapeutics. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol NKTR Asset equity Sector Markets 90 days 5 Last 72.975 Updated Aug 13, 2026, 08:15 PM UTC Open live news feed
L Nektar Therapeutics reports Second Quarter 2026 financial results Nektar Therapeutics (NKTR) announces its Second Quarter 2026 financial results, but the feed provides no further figures or guidance details. EARNINGS | Aug 13, 2026, 08:15 PM UTC L NKTR NKTR - Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets NKTR NKTR - Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets EARNINGS | Jul 28, 2026, 10:00 PM UTC L NKTR Maintain Buy and $151 PT after Ph3 Initiation in Ad Marks Key Milestone for Rezpeg @ Citi NKTR Maintain Buy and $151 PT after Ph3 Initiation in Ad Marks Key Milestone for Rezpeg @ Citi EQUITY | Jul 22, 2026, 01:08 PM UTC L NKTR Initiated Buy W/$153.00 PT at Canaccord NKTR Initiated Buy W/$153.00 PT at Canaccord EQUITY | Jul 22, 2026, 12:02 PM UTC L NKTR Nektar Therapeutics announces start of phase 3 zenith Ad program evaluating novel regulatory T-cell biologic rezpegaldesleukin in moder NKTR Nektar Therapeutics announces start of phase 3 zenith Ad program evaluating novel regulatory T-cell biologic rezpegaldesleukin in moderate-to-severe atopic dermatitis Nektar Therapeutics - initial phase 3 topline da EQUITY | Jul 21, 2026, 11:04 AM UTC